The Surgical Investigator Program supports clinical and translational research by young cardiothoracic surgeons, including topics related to quality and outcomes research, and studies of new and innovative therapies, procedures, and technologies in cardiothoracic surgery. While this program is designed to support early-career development, in 2021, the AstraZeneca sponsored Surgical Investigator award has been specifically designated for mid-career clinical scientists, detail below.
Spring 2021 Available Awards
AstraZeneca Surgical Investigator Award
Awards up to $100,000 annually (for up to two years) to support research proposals focused on the treatment of lung cancer, either in terms of basic science advances, surgical outcomes or the development of quality initiatives. Proposals could be focused on topics such as the following:
- Patient reported outcomes after surgery, specifically as they relate to disease free survival or recurrence.
- Pre- and post-operative molecular testing.
- Optimization of staging and or definition of surgical quality metrics.
- Prognostic biomarkers in patients with surgically resected lung cancer.